Condition: Non-cystic Fibrosis Bronchiectasis · Sponsor: Reistone Biopharma Company Limited
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT/QTc interval.
This description comes directly from the study's public registry record.
Ye Xu · +86-0518-81220121 · ye.xu.yx1@hengrui.com
Always discuss trial participation with your own doctor first.
| Zhongnan Hospital of Wuhan University | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07289464